Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle

BACKGROUND: The development of anti-drug antibodies (ADA) in patients treated with therapeutic proteins can result in treatment failure. The clinically most relevant fraction of these antibodies are the neutralizing anti-drug antibodies (NAb) that block the pharmacological function of the drug. Cons...

Descripción completa

Detalles Bibliográficos
Autores principales: El Amrani, Mohsin, Göbel, Camiel, Egas, Annelies C., Nierkens, Stefan, Hack, C. Erik, Huitema, Alwin D.R., van Maarseveen, Erik M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388346/
https://www.ncbi.nlm.nih.gov/pubmed/32743494
http://dx.doi.org/10.1016/j.jtauto.2019.100004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388346/
https://www.ncbi.nlm.nih.gov/pubmed/32743494
http://dx.doi.org/10.1016/j.jtauto.2019.100004

Ejemplares similares